Davern Capital Partners
LEGN icon

Davern Capital Partners’s Legend Biotech LEGN Stock Holding History

Davern Capital Partners’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$16.5M Sell
828,880
-362,642
-30% -$7.74M 3.21% 12
2026
Q2 		$34.4M Sell
1,191,522
-123,226
-9% -$3.32M 5.87% 7
2026
Q1 		$23.8M Buy
1,314,748
+258,080
+24% +$4.92M 6.52% 11
2025
Q4 		$23M Buy
+1,056,668
New +$30.3M 7.43% 6

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Triata Capital
Triata Capital Hong Kong $531M AUM 34.32% 1-Year Est. Return
Matthews International Capital Management
Matthews International Capital Management San Francisco, California $241M AUM 42.66% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Davern Capital Partners's LEGN Position: Q3 2026 in Review

Davern Capital Partners reduced its Legend Biotech (LEGN) stake by 30% in Q3 2026, selling an estimated $7.74M and leaving 828,880 shares worth $16.5M. The position accounts for 3.21% of the portfolio, ranked #12.

Davern Capital Partners first reported a position in LEGN in Q4 2025 and has held it in 4 quarters since. The position peaked at $34.4M in Q2 2026. 144 funds tracked by Wall St. Rank hold LEGN as of Q3 2026.

  • Davern Capital Partners held 828,880 shares of Legend Biotech worth $16.5M as of Q3 2026.
  • Davern Capital Partners sold 362,642 Legend Biotech shares in Q3 2026, an estimated $7.74M.
  • Legend Biotech made up 3.21% of Davern Capital Partners's portfolio in Q3 2026, its #12 holding.
  • Davern Capital Partners first reported a position in Legend Biotech in Q4 2025 and has held it in 4 quarters since.
  • Davern Capital Partners's Legend Biotech position peaked at $34.4M in Q2 2026.
  • 144 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2026.

Based on Davern Capital Partners's 13F filing for Q3 2026, filed 12 Nov 2026.